| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 94.80 | -8 |
| Intrinsic value (DCF) | 83.74 | -19 |
| Graham-Dodd Method | 5.10 | -95 |
| Graham Formula | 76.60 | -26 |
Zoetis Inc. (ZOE.DE) is a global leader in animal health, specializing in the discovery, development, manufacturing, and commercialization of medicines, vaccines, and diagnostic products for both livestock and companion animals. Headquartered in Parsippany, New Jersey, Zoetis serves veterinarians, livestock producers, and retail outlets through a diversified portfolio that includes vaccines, anti-infectives, parasiticides, dermatology products, and precision animal health solutions. The company operates in a high-growth sector driven by increasing pet ownership, rising demand for protein, and advancements in veterinary care. With a strong presence in the U.S. and international markets, Zoetis leverages its scientific expertise and extensive distribution network to maintain its leadership in the $50+ billion animal health industry. Its commitment to innovation and sustainability positions it as a key player in improving animal welfare and supporting food security worldwide.
Zoetis presents a compelling investment opportunity due to its dominant position in the resilient and growing animal health market. The company benefits from consistent revenue streams driven by essential veterinary products and increasing global demand for livestock and companion animal care. With a market cap of €63.3 billion, strong profitability (net income of €2.5 billion in FY 2023), and robust cash flow (€2.95 billion operating cash flow), Zoetis demonstrates financial stability. However, risks include exposure to regulatory changes, competition from generics, and macroeconomic pressures affecting livestock producers. The stock’s beta of 0.94 suggests lower volatility than the broader market, appealing to conservative investors. A dividend yield of ~0.7% (€1.77 per share) adds income appeal, though growth prospects hinge on innovation and international expansion.
Zoetis holds a competitive edge as the largest standalone animal health company, spun off from Pfizer in 2013. Its scale allows for significant R&D investment (€925.6 million revenue in FY 2023), yielding a pipeline of high-margin biologics and diagnostics. The company’s broad portfolio spans livestock and companion animals, reducing dependence on any single segment. Zoetis outperforms peers in dermatology (e.g., Apoquel for canine allergies) and parasiticides (e.g., Simparica), with strong brand loyalty among veterinarians. Its direct-to-veterinarian sales model ensures sticky customer relationships, while competitors often rely on third-party distributors. However, Zoetis faces pressure from generics in parasiticides and vaccines, where Elanco and Merck Animal Health are aggressive. In livestock, its medicated feed additives compete with low-cost alternatives in emerging markets. Zoetis mitigates these risks through premium branding and precision livestock solutions (e.g., monitoring technologies), though its debt (€6.7 billion) is higher than some peers’.